Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
NCT00226239
Completed
The purpose of this study is to determine if the addition of a unique targeted agent called Cetuximab (also known as "C225" and "Erbitux") can increase the effectiveness of standard treatment with chemotherapy and radiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2017
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Cancer
Register for Updates
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
NCT00394433
Completed
The purpose of this research study is to determine if the combination of docetaxel, cisplatin, irinotecan and bevacizumab will help shrink metastatic esophageal or gastric cancer and how the cancer responds to this combination. Bevacizumab is a new drug that is believed to stop the formation of new blood vessels that carry nutrients to tumors. Bevacizumab is approved for use in metastatic colon and rectal cancer. Docetaxel, cisplatin and irinotecan are traditional chemotherapy agents that have b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/05/2017
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Esophageal Cancer, Stomach Cancer
Register for Updates
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
NCT00102531
Completed
Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients with relapsed/progressive osteosarcoma metastatic to the lung.
Gender:
ALL
Ages:
Between 13 years and 50 years
Trial Updated:
07/05/2017
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +1 locations
Conditions: Osteosarcoma Metastatic
Register for Updates
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
NCT01911598
Completed
This open-label, multicenter study will evaluate the safety, tolerability, and pharmacokinetics of MEHD7945A in combination with chemotherapy (either cisplatin plus 5-FU or carboplatin plus paclitaxel) in participants with previously untreated R/M SCCHN. There are two stages for each arm in this study: a Dose-limiting Toxicity (DLT)-evaluation stage (Stage I) and a cohort-expansion stage (Stage II). In Stage I, DLTs will be assessed during a DLT Assessment Window of 21 days (i.e., Cycle 1 Day 1... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2017
Locations: University of Colorado Cancer Center Department of Hematology, Aurora, Colorado +5 locations
Conditions: Head and Neck Cancer
Register for Updates
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
NCT00304278
Completed
The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2017
Locations: Simmons Cooper Cancer Institute/SIU School of Medicine, Springfield, Illinois
Conditions: Head and Neck Cancer
Register for Updates
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
NCT02107235
Completed
The working hypothesis is that oral rigosertib treatment when added to platinum-based Chemoradiotherapy (CRT) will improve progression-free survival for first-line patients with intermediate- or high-risk human papillomavirus negative positive (HPV (+)) Head and Neck Squamous Cell Carcinoma. This study will determine the highest safe dose of oral rigosertib that can be used with cisplatin and CRT. This study will also record any side effects that may occur and measure tumor sizes and how long pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/22/2017
Locations: University of Colorado Cancer Center, Aurora, Colorado +3 locations
Conditions: Head and Neck Neoplasms, Carcinoma, Squamous Cell
Register for Updates
Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
NCT00248495
Completed
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them before and after surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving pemetrexed disodium and cisplatin before and after surgery works in treating patients with stage I, stage II, or stage... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/15/2017
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Lung Cancer
Register for Updates
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
NCT00062374
Completed
This phase II trial is studying how well giving irinotecan together with cisplatin works in treating patients who are undergoing surgical resection for locally advanced cancer of the stomach or gastroesophageal junction. Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and giving them before surgery may shrink the tumor so that it can be removed during surg... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2017
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
Register for Updates
Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
NCT00511992
Completed
The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2017
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Carcinosarcoma
Register for Updates
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
NCT01409174
Terminated
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of the drug Yervoy (ipilimumab) that can be given with the drugs Temodar (temozolomide), Intron-A (interferon alfa-2b), Proleukin (aldesleukin, IL-2), and Platinol (cisplatin) to patients with metastatic melanoma. The safety of this combination will also be studied in Phase I. The goal of Phase II is to learn if this combination can help to control metastatic melanoma. Note: The study was closed fo... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/26/2017
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma
Register for Updates
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
NCT02856568
Withdrawn
This phase Ib trial studies the side effects and best dose of ricolinostat when given together with gemcitabine hydrochloride and cisplatin in treating patients with cholangiocarcinoma that cannot be removed by surgery or has spread to other places in the body. Ricolinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/25/2017
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Non-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Extrahepatic Bile Duct Cancer, Stage III Intrahepatic Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Hilar Cholangiocarcinoma, Stage IVA Extrahepatic Bile Duct Cancer, Stage IVA Hilar Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVB Extrahepatic Bile Duct Cancer, Stage IVB Hilar Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma, Unresectable Extrahepatic Bile Duct Carcinoma
Register for Updates
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
NCT01918306
Terminated
This phase I/II trial study evaluates the tolerability and best tolerated dose of the PI3K inhibitor GDC-0941 when given with the chemotherapy cisplatin. This study will also examine how well the combination of GDC-0941 and cisplatin work in treating patients with androgen receptor negative triple negative metastatic breast cancer. Patients will be randomized to receive cisplatin alone or cisplatin with GDC-0941 in the phase II portion. Those receiving cisplatin alone can receive GDC-0941 upon p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2017
Locations: University of Alabama, Birmingham, Alabama +15 locations
Conditions: Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Register for Updates